1López-Tarruella S,Martín M,et al Recent advances in systemictherapy:advances in adjuvant systemic chemotherapy of earlybreast cancer[J].Breast Cancer Res,2009,11:204.
5Kubota T,Furukawa T,Tanino H.et al.Pirarubicin might partlycircumvent the P-glycoprotein-mediated drug resistance of humanbreast cancer tissues[J].Anticancer Res,1998,18:967-972.
6Williugbam C C, Pastan I. Image intensification techniques for detection of proteins in cultured cell by fluo rescence microscopy [ J ]. Methods Enzymol, 1993,98:266.
7Blumenschein GR, Cardenas JO,Freireich EJ,et al.FAC combination chemotherapy for metastatic breast cancer[J].Proc Am Assoc Cancer Rer,1974,15:193.
8Tatuo S, Yoichi K, Akira W, et al. Multi-institutional cooperative study. Phase II study of(2''R)-4-O-tetrahy dropyranyladriamycin(THP) in patients with solid tumors[J]. Jpn J Cancer Chemother,1986,13(4):1060.
10Diaz-canton EA,Valero V, Rahman Z,et al. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy[J]. ANN Oncol,1998,9(4):413.
5Ran S. Volk L,Hall K,et al. Lymphangiogenesis and lymphatic metas-tasis in breast cancer[J],Pathophysiology,2010,17(4):229-251.
6Zhu C,Qi X,Chen Y,et al. PI3K/Akt and MAPK/ERK1/2 sig-naling pathways are involved in IGF-1-induced VEGF-C upregu-lation in breast cancer[J].J Cancer Res Clin Oncol,2011.137(11):1587-1594.
7Chau NM,Ashcroft M. Akt2; a role in breast cancer metastasis[J].Breast Cancer Res,2004,6(l) :55-57.
8Kurenova EV. Hunt DL,He D,et al. Vascular endothelial growthfactor receptor-3 promotes breast cancer cell proliferation,motilityand survival in vitro and tumor formation in vivo [J].Cell Cycle,2009,8(14):2266-2280.
